KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Income from Continuing Operations (2017 - 2025)

Moderna (MRNA) has disclosed Income from Continuing Operations for 9 consecutive years, with 826000000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 26.25% to 826000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 2822000000.0, a 20.75% increase, with the full-year FY2025 number at 2822000000.0, up 20.75% from a year prior.
  • Income from Continuing Operations was 826000000.0 for Q4 2025 at Moderna, down from 200000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 4868000000.0 in Q4 2021 to a low of 3630000000.0 in Q3 2023.
  • A 5-year average of 473350000.0 and a median of 46000000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: surged 2484.94% in 2021, then tumbled 1638.46% in 2025.
  • Moderna's Income from Continuing Operations stood at 4868000000.0 in 2021, then plummeted by 69.91% to 1465000000.0 in 2022, then crashed by 85.19% to 217000000.0 in 2023, then crashed by 616.13% to 1120000000.0 in 2024, then increased by 26.25% to 826000000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Income from Continuing Operations are 826000000.0 (Q4 2025), 200000000.0 (Q3 2025), and 825000000.0 (Q2 2025).